ALSO NOTED: Rosetta cuts share price; FDA committee to focus on Pentacel; and much more...

> Rosetta Genomics has cut the price range for its IPO to $7.50 to $8.50 a share. Report

> An FDA advisory committee will examine safety and efficacy issues surrounding the vaccine Pentacel from Sanofi-Aventis. Report

> Molecular Insight Pharmaceuticals has inked a licensing deal to develop and sell Onalta, a radiotherapeutic candidate, from Novartis. No financial details were released. Release

> GPC Biotech has raised € 33.6 million in a private placement. Release

> Chutes & Ladders: John Dyer is moving from CMS to the FDA, where he will be the deputy commissioner for operations and the new COO. Report

And Finally... A new study says that learning can slow the development of brain lesions in Alzheimer's. Report